Verona Pharma ready to turn excitement into commercial usefulness, says CEO Jan-Anders Karlsson

29 October 2017

As with many emerging biotech companies, shares in UK-based Verona Pharma (Nasdaq: VRNA) have jumped around a fair bit as markets make their predictions on whether its leading asset is as good as it says it is.

Now the evidence is starting to show that Verona’s RPL554 might just deliver in the way that the company, investors and a huge and desperate patient group hope that it does.

In the last two months, Verona has published positive results from two studies on RPL554 in its major indication of chronic obstructive pulmonary disorder (COPD), a respiratory condition with 384 million diagnosed patients globally and no current cure.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK